Tumor Hypoxia Directed Multimodal Nanotherapy for Overcoming Drug Resistance in Renal Cell Carcinoma and Reprogramming Macrophages

Drug resistance is one of the significant clinical burden in renal cell carcinoma (RCC). The development of drug resistance is attributed to many factors, including impairment of apoptosis, elevation of carbonic anhydrase IX (CA IX, a marker of tumor hypoxia), and infiltration of tumorigenic immune...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Biomaterials
Egile Nagusiak: Alsaab, Hashem O., Sau, Samaresh, Alzhrani, Rami M., Cheriyan, Vino T., Polin, Lisa A., Vaishampayan, Ulka, Rishi, Arun K., Iyer, Arun K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6414719/
https://ncbi.nlm.nih.gov/pubmed/30179778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biomaterials.2018.08.053
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak